Digital Health & Pharma R&D
Bristol Myers Using Anthropic’s Claude AI to Speed Drug Discovery
By Intent.Health Team • May 20, 2026
What’s happening
Bristol Myers Squibb is deploying Anthropic’s Claude AI model to help accelerate drug discovery and pharmaceutical research.
The AI will help researchers:
- analyze scientific data
- speed up research workflows
- identify drug development insights faster
What’s changing / Business impact
Increased use of:
- generative AI, pharmaceutical AI tools, and automated research systems
Tech companies becoming deeply integrated into:
- biotech and pharmaceutical R&D
Why this matters
Traditional drug development historically takes years, costs billions, and has high failure rates.
This shows pharmaceutical companies believe AI may significantly reduce research time and costs, signaling that AI is becoming part of core healthcare infrastructure.
CORE TAKEAWAY
AI is increasingly moving from experimental healthcare tech into real pharmaceutical operations.